These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 16302413)

  • 21. [Cost effectiveness in the Danish health care of ezetemibe co-administration compared to simvastatin].
    Keiding H; Hildebrandt P; Alemao E; Davies GM
    Ugeskr Laeger; 2008 Jun; 170(26-32):2323-6. PubMed ID: 18570764
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study.
    Roeters van Lennep HW; Liem AH; Dunselman PH; Dallinga-Thie GM; Zwinderman AH; Jukema JW
    Curr Med Res Opin; 2008 Mar; 24(3):685-94. PubMed ID: 18226326
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination therapy with ezetimibe and simvastatin to achieve aggressive LDL reduction.
    Robinson JG; Davidson MH
    Expert Rev Cardiovasc Ther; 2006 Jul; 4(4):461-76. PubMed ID: 16918265
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe.
    Daskalopoulou SS; Mikhailidis DP
    Curr Med Res Opin; 2006 Mar; 22(3):511-28. PubMed ID: 16574035
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Considerable remaining risk in unchecked LDL lowering. Is the HDL increase the way out?].
    MMW Fortschr Med; 2006 Jun; 148(24):6, 8. PubMed ID: 16856232
    [No Abstract]   [Full Text] [Related]  

  • 26. Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients.
    Catapano AL; Davidson MH; Ballantyne CM; Brady WE; Gazzara RA; Tomassini JE; Tershakovec AM
    Curr Med Res Opin; 2006 Oct; 22(10):2041-53. PubMed ID: 17022864
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The new debate on cholesterol: is the lowest level the best?].
    Olsson AG
    Lakartidningen; 1999 Feb; 96(6):648-52. PubMed ID: 10087815
    [No Abstract]   [Full Text] [Related]  

  • 28. [LDL cholesterol in cardiovascular risk patients should be as low as possible].
    MMW Fortschr Med; 2007 Oct; 149(41):44-5. PubMed ID: 17992793
    [No Abstract]   [Full Text] [Related]  

  • 29. [Risk patients are often insufficiently treated. LDL cholesterol to be held down even more vigorously].
    MMW Fortschr Med; 2004 Oct; 146(44):56-7. PubMed ID: 15566253
    [No Abstract]   [Full Text] [Related]  

  • 30. [The lower LDL cholesterol the better!].
    Stenestrand U; Olsson AG
    Lakartidningen; 2004 Oct; 101(42):3246-7. PubMed ID: 15544130
    [No Abstract]   [Full Text] [Related]  

  • 31. Co-administration of ezetimibe and simvastatin in acute myocardial infarction.
    Chenot F; Montant PF; Marcovitch O; Blaimont M; de Meester A; Descamps OS
    Eur J Clin Invest; 2007 May; 37(5):357-63. PubMed ID: 17461981
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Is there a problem with ezetimibe or just ENHANCEd hype?
    Whayne TF
    Angiology; 2008 Dec-2009 Jan; 59(6):661-3. PubMed ID: 18796445
    [No Abstract]   [Full Text] [Related]  

  • 33. [Heart Protection Study].
    Larsen ML; Hildebrandt PR
    Ugeskr Laeger; 2002 Jan; 164(3):348. PubMed ID: 11816337
    [No Abstract]   [Full Text] [Related]  

  • 34. [Better with lower LDL cholesterol! Aim at 2 mmol/l for secondary prevention].
    Olsson AG
    Lakartidningen; 2006 Jan 11-17; 103(1-2):22-3. PubMed ID: 16465841
    [No Abstract]   [Full Text] [Related]  

  • 35. Drug insight: the role of statins in combination with ezetimibe to lower LDL cholesterol.
    Gotto AM; Farmer JA
    Nat Clin Pract Cardiovasc Med; 2006 Dec; 3(12):664-72. PubMed ID: 17122799
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Simvastatin 40 mg as secondary prophylaxis: Effective, tolerable and cost-efficient!].
    Hernborg A; Hjemdahl P; Håkansson J
    Lakartidningen; 2006 Mar 15-21; 103(11):858, 861; discussion 861-2. PubMed ID: 16613120
    [No Abstract]   [Full Text] [Related]  

  • 37. [The surprising (?) results of IMPROVE-IT].
    Poli A
    G Ital Cardiol (Rome); 2015 May; 16(5):281-3. PubMed ID: 25994463
    [No Abstract]   [Full Text] [Related]  

  • 38. Biomarkers and surrogate endpoints in cardiovascular therapeutics research: under scrutiny following results of the ENHANCE Study.
    Pauriah M; Struthers AD; Lang CC
    Cardiovasc Ther; 2008; 26(2):85-8. PubMed ID: 18485130
    [No Abstract]   [Full Text] [Related]  

  • 39. Clinical experience with ezetimibe/simvastatin in a Mediterranean population.
    Migdalis I; Efthimiadis A; Pappas S; Alexopoulos D; Vlasserou F; Mikhailidis DP
    Curr Med Res Opin; 2009 Oct; 25(10):2571-6. PubMed ID: 19739939
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lipid-altering efficacy of ezetimibe/simvastatin 10/40 mg compared with doubling the statin dose in patients admitted to the hospital for a recent coronary event: the INFORCE study.
    Reckless JP; Henry P; Pomykaj T; Lim ST; Massaad R; Vandormael K; Johnson-Levonas AO; Lis K; Brudi P; Allen C
    Int J Clin Pract; 2008 Apr; 62(4):539-54. PubMed ID: 18266852
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.